Cargando…

Oncolytic viruses for triple negative breast cancer and beyond

Biological therapy is considered an alternative treatment capable of eliciting the same effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in biological therapy, oncolytic viruses (OVs) have attracted great attention and achieved good results. Specifically, the successfu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Shengye, Wang, Qin, Wu, Hao, Pang, Da, Xu, Shouping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466906/ https://www.ncbi.nlm.nih.gov/pubmed/34563270 http://dx.doi.org/10.1186/s40364-021-00318-4

Ejemplares similares

Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses
por: Monaco, Michael L., et al.
Publicado: (2023)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
por: Green-Tripp, Gabriela, et al.
Publicado: (2022)

Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer
por: Behrens, Marshall D., et al.
Publicado: (2022)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

Nanoblock-mediated selective oncolytic polypeptide therapy for triple-negative breast cancer
por: Zhong, Cuiyu, et al.
Publicado: (2023)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
por: Ghouse, Shanawaz M., et al.
Publicado: (2020)

Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
por: Thomas, Raquela J., et al.
Publicado: (2023)

Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-κB-VCAM-1 Signaling Pathway
por: Wu, Hao, et al.
Publicado: (2021)

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses
por: Cassady, Kevin A., et al.
Publicado: (2016)

Unconventional protein post-translational modifications: the helmsmen in breast cancer
por: Liu, Jiena, et al.
Publicado: (2022)

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
por: Wang, Lihong, et al.
Publicado: (2022)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
por: Ziogas, Dimitrios C., et al.
Publicado: (2022)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way
por: Li, Wei, et al.
Publicado: (2021)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus
por: Wan, Peter Kok-Ting, et al.
Publicado: (2021)

Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses
por: Hoare, Joseph, et al.
Publicado: (2018)

Dual effects of N(6)-methyladenosine on cancer progression and immunotherapy
por: Li, Hui, et al.
Publicado: (2021)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Theranostics for Triple-Negative Breast Cancer
por: Choi, Hyeryeon, et al.
Publicado: (2023)

Systematic characterization of non‐coding RNAs in triple‐negative breast cancer
por: Mei, Jie, et al.
Publicado: (2020)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

Metabolic reprogramming in triple-negative breast cancer
por: Wang, Zhanyu, et al.
Publicado: (2020)

Crosstalk between triple negative breast cancer and microenvironment
por: Smrekar, Karly, et al.
Publicado: (2023)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Oncolytic viruses: A novel treatment strategy for breast cancer
por: Javanbakht, Mohammad, et al.
Publicado: (2021)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

MicroRNAs and Triple Negative Breast Cancer
por: D’Ippolito, Elvira, et al.
Publicado: (2013)

Triple negative breast cancer: the kiss of death
por: Jitariu, Adriana-Andreea, et al.
Publicado: (2017)

Wnt signaling in triple-negative breast cancer
por: Pohl, SÖ-G, et al.
Publicado: (2017)

Estrogen Actions in Triple-Negative Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2020)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6h38f31g7ih0r01crjatcrf7pl